NASDAQ:RYTMRhythm Pharmaceuticals Stock Price, Forecast & News

Rhythm Pharmaceuticals' stock was trading at $15.00 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, RYTM shares have increased by 22.6% and is now trading at $18.39.
View which stocks have been most impacted by COVID-19.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Rhythm Pharmaceuticals in the last year. There are currently 1 sell rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Rhythm Pharmaceuticals.

Rhythm Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Friday, November 6th 2020.
View our earnings forecast for Rhythm Pharmaceuticals.

Rhythm Pharmaceuticals Inc (NASDAQ:RYTM) announced its quarterly earnings data on Monday, August, 3rd. The company reported ($0.71) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.83) by $0.12.
View Rhythm Pharmaceuticals' earnings history.

7 equities research analysts have issued 1 year price targets for Rhythm Pharmaceuticals' stock. Their forecasts range from $18.00 to $43.00. On average, they expect Rhythm Pharmaceuticals' stock price to reach $33.71 in the next twelve months. This suggests a possible upside of 83.3% from the stock's current price.
View analysts' price targets for Rhythm Pharmaceuticals.

News articles about RYTM stock have trended positive recently, according to InfoTrie. The research group scores the sentiment of news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Rhythm Pharmaceuticals earned a media sentiment score of 2.7 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the stock's share price in the next few days.
View the latest news about Rhythm Pharmaceuticals.

Rhythm Pharmaceuticals saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 1,810,000 shares, an increase of 25.7% from the April 30th total of 1,440,000 shares. Based on an average daily trading volume, of 252,700 shares, the short-interest ratio is presently 7.2 days. Approximately 5.4% of the shares of the company are sold short.
View Rhythm Pharmaceuticals' Short Interest.

Some companies that are related to Rhythm Pharmaceuticals include PTC Therapeutics (PTCT), Opko Health (OPK), Insmed (INSM), Axsome Therapeutics (AXSM), Alkermes (ALKS), Agios Pharmaceuticals (AGIO), Principia Biopharma (PRNB), CytoDyn (CYDY), SAGE Therapeutics (SAGE), Amarin (AMRN), Deciphera Pharmaceuticals (DCPH), Pacira Biosciences (PCRX), Taro Pharmaceutical Industries (TARO), Karuna Therapeutics (KRTX) and Turning Point Therapeutics (TPTX).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Rhythm Pharmaceuticals investors own include Agile Therapeutics (AGRX), Amarin (AMRN), Exelixis (EXEL), Intra-Cellular Therapies (ITCI), Myovant Sciences (MYOV), Nabriva Therapeutics (NBRV), Nektar Therapeutics (NKTR), Sarepta Therapeutics (SRPT), VBI Vaccines (VBIV) and Viking Therapeutics (VKTX).

(RYTM) raised $100 million in an initial public offering on Thursday, October 5th 2017. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, BofA Merrill Lynch and Cowen acted as the underwriters for the IPO and Needham was co-manager.

Rhythm Pharmaceuticals trades on the NASDAQ under the ticker symbol "RYTM."

Rhythm Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include MPM Asset Management LLC (4.33%), Marshall Wace North America L.P. (0.68%), Bank of New York Mellon Corp (0.29%), Barclays PLC (0.23%), Bessemer Group Inc. (0.20%) and California Public Employees Retirement System (0.15%). Company insiders that own Rhythm Pharmaceuticals stock include Der Ploeg Leonardus HT Van, Keith Michael Gottesdiener, Nithya Desikan, Ra Capital Management, LP and Todd Foley.
View institutional ownership trends for Rhythm Pharmaceuticals.

RYTM stock was sold by a variety of institutional investors in the last quarter, including MPM Asset Management LLC, Goldman Sachs Group Inc., and Swiss National Bank. Company insiders that have sold Rhythm Pharmaceuticals company stock in the last year include Nithya Desikan, Ra Capital Management, LP, and Todd Foley.
View insider buying and selling activity for Rhythm Pharmaceuticals.

RYTM stock was purchased by a variety of institutional investors in the last quarter, including Marshall Wace North America L.P., Bessemer Group Inc., Athanor Capital LP, ProShare Advisors LLC, Bank of New York Mellon Corp, Marshall Wace LLP, Principal Financial Group Inc., and Matisse Capital.
View insider buying and selling activity for Rhythm Pharmaceuticals.

Shares of RYTM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of RYTM stock can currently be purchased for approximately $18.39.

Rhythm Pharmaceuticals has a market capitalization of $811.35 million. The company earns $-140,730,000.00 in net income (profit) each year or ($3.86) on an earnings per share basis. Rhythm Pharmaceuticals employs 54 workers across the globe.

The official website for Rhythm Pharmaceuticals is www.rhythmtx.com.

Rhythm Pharmaceuticals' mailing address is 222 BERKELEY STREET 12TH FLOOR, BOSTON MA, 02116. The company can be reached via phone at 857-264-4280 or via email at [email protected]